MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK; Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, Cardiff, UK.
Clinic for Psychiatry, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Eur J Med Genet. 2020 Dec;63(12):104093. doi: 10.1016/j.ejmg.2020.104093. Epub 2020 Nov 5.
Several rare copy number variants have been identified to confer risk for neurodevelopmental disorders (NDD-CNVs), and increasingly NDD-CNVs are being identified in patients. There is a clinical need to understand the phenotypes of NDD-CNVs. However due to rarity of NDD-CNVs in the population, within individual countries there is a limited number of NDD-CNV carriers who can participate in research. The pan-european MINDDS (Maximizing Impact of Research in Neurodevelopmental Disorders) consortium was established in part to address this issue.
A survey was developed to scope out the current landscape of NDD-CNV research across member countries of the MINDDS consortium, and to identify clinical cohorts with potential for future research.
36 centres from across 16 countries completed the survey. We provide a list of centres who can be contacted for future collaborations. 3844 NDD-CNV carriers were identified across clinical and research centres spanning a range of medical specialties, including psychiatry, paediatrics, medical genetics. A broad range of phenotypic data was available; including medical history, developmental history, family history and anthropometric data. In 12/16 countries, over 75% of NDD-CNV carriers could be recontacted for future studies.
This survey has highlighted the potential within Europe for large multi-centre studies of NDD-CNV carriers, to improve knowledge of the complex relationship between NDD-CNV and clinical phenotype. The MINNDS consortium is in a position to facilitate collaboration, data-sharing and knowledge exchange on NDD-CNV phenotypes across Europe.
已经发现了几种罕见的拷贝数变异可导致神经发育障碍(NDD-CNV),并且越来越多的 NDD-CNV 正在患者中被发现。因此,需要了解 NDD-CNV 的表型。但是,由于 NDD-CNV 在人群中的罕见性,在单个国家中,能够参与研究的 NDD-CNV 携带者数量有限。泛欧 MINDDS(最大限度地提高神经发育障碍研究的影响)联盟的建立部分是为了解决这个问题。
开发了一项调查,以了解 MINDDS 联盟成员国的 NDD-CNV 研究现状,并确定具有未来研究潜力的临床队列。
来自 16 个国家的 36 个中心完成了调查。我们提供了可以联系的中心列表,以便未来进行合作。跨越包括精神病学、儿科学、医学遗传学在内的一系列医学专业的临床和研究中心共鉴定出 3844 名 NDD-CNV 携带者。提供了广泛的表型数据,包括病史、发育史、家族史和人体测量数据。在 16 个国家中的 12 个国家中,超过 75%的 NDD-CNV 携带者可以重新联系以进行未来的研究。
这项调查突出了欧洲在 NDD-CNV 携带者进行大型多中心研究的潜力,以提高对 NDD-CNV 与临床表型之间复杂关系的认识。MINNDS 联盟能够在整个欧洲促进 NDD-CNV 表型的合作、数据共享和知识交流。